Skip to content
Search

Latest Stories

House of Common debates on puberty blockers and pharmacists' challenges over prescription

House of Common debates on puberty blockers and pharmacists' challenges over prescription
MPs discussed the UK's approach to prescribing puberty blockers for gender incongruence, emphasising the challenges pharmacists face with overseas prescriptions

"Not possible for pharmacists to check whether prescriptions issued from overseas registered prescribers have been issued in a similarly safe and effective way," the new Minister of State (Department of Health and Social Care) Karin Smyth said during a recent parliamentary written response.

At a recent session on Monday, July 29th, at the House of Commons, MP Cat Smith raised an important question directed at the Secretary of State for Health and Social Care.


Smith, who represents Lancaster and Wyre, and has been an MP continually since 7 May 2015, inquired about whether the Department of Health and Social Care had conducted a comparative assessment of the UK's stance on prescribing puberty blockers for treating gender incongruence in comparison to other European countries.

Responding to the questions, MP Karin Smyth emphasised on the significance of the Cass Review and described it as one of the most thorough examinations conducted across the globe on gender identity services for children and young people.

Smyth highlighted that the Cass Review published earlier this year included an evaluation of evidence procured internationally and concluded that "there was a lack of evidenced-based guidelines and, therefore, limitations for adopting these for National Health Service gender services".

She also highlighted that the government is in the process of reforming transgender care for young people in this country, based on the best possible evidence.

"That means a holistic approach, with puberty suppressing hormones only considered within a much broader needs assessment, and only then in the context of a clinical trial."

Addressing the concern of overseas prescription, she noted the challenges faced by the pharmacists to verify the safety and efficacy of the prescriptions provided by an overseas medical professionals.

"We know that some overseas providers who advertise their services do not follow this approach," she stated raising concerns about the consistency and safety of such treatments.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less